MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--SanBio, Inc., a scientific leader in regenerative medicine, today announced it has been granted a key patent by the United States Patent and Trademark Office (USPTO) covering its proprietary modified stem cells, SB623, for the treatment of retinal degeneration. SanBio developed SB623 to promote regenerative processes in the central nervous system and provide therapeutic options for debilitating neurological disorders, including retinal degeneration.
United States Patent No. 9,326,999 B2 was formally granted on May 3, 2016 and covers, among other things, the use of SB623 cells in treating retinal degeneration by enhancing photoreceptor function.
Retinal degeneration, which includes age-related macular degeneration and retinitis pigmentosa, causes a reduction in visual acuity and can lead to blindness. There are currently no proven medical treatment options for macular degeneration.
Said Dr. Damien Bates, Chief Medical Officer at SanBio, “This patent is an important step in expanding the application of SanBio’s regenerative medicine, SB623, to treat retinal degeneration, one of the leading causes of blindness. We hope this product can provide some hope for the 15 million Americans with dry age-related macular degeneration, currently for which there is no cure.”
SanBio has also previously received patents protecting the methods for treating stroke with SB623 cells.
About SanBio, Inc. (SanBio)
SanBio is a regenerative medicine company headquartered in Tokyo and Mountain View, California, with cell-based products in various stages of research, development and clinical trials. Its proprietary cell-based product, SB623, is currently in a Phase 2b clinical trial for treatment of chronic motor impairments resulting from ischemic stroke. SanBio also began a Phase 2 clinical trial for treatment of motor impairment resulting from traumatic brain injury in late 2015. More information about SanBio, Inc. is available at http://san-bio.com.